Prostate MRI is commonly used in the detection of prostate cancer to reduce the detection of clinically insignificant disease; maximize the detection of clinically significant cancer; and better assess disease size, grade, and location. The clinical utility of MRI seems to apply to men with no prior biopsy, who have had a previous negative biopsy, and men who are candidate for active surveillance. In conjunction with traditional clinical parameters and secondary biomarkers, MRI may allow more accurate risk stratification and assessment of need for prostate biopsy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ucl.2017.07.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rectal Gas-Induced Dose Changes in Carbon Ion Radiation Therapy for Prostate Cancer: An In Silico Study.
Int J Part Ther
March 2025
Department of Heavy Particle Medical Science, Yamagata University Graduate School of Medical Science, Yamagata, Japan.
Purpose: This study aims to determine dosimetric influence of rectal gas in carbon ion radiation therapy (CIRT) for prostate cancer and to establish a procedure for removal rectal gas in clinical scenarios.
Materials And Methods: We analyzed 18 prostate cancer cases with bulky rectal gas. The dose distribution was recalculated on computed tomography (CT) with bulky rectal gas (gasCT) after creating the initial plan on a CT without bulky rectal gas, and the doses were transformed using a displacement vector field.
Impact of National Comprehensive Cancer Network Guidelines Inclusion of Level 1 Evidence on Insurance Denial for Randomized Controlled Trial Patients with Metastatic Spine Disease.
Rep Pract Oncol Radiother
December 2024
Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
Background: The primary treatment of metastatic spine disease is radiation therapy (RT), traditionally conventional external beam RT (EBRT) or stereotactic body RT (SBRT). Until recently, there had been no Level 1 evidence supporting SBRT over EBRT, which has led to difficulties obtaining insurance approval. Publication of the first randomized controlled trial (RCT) comparing SBRT to EBRT for spine metastases [Canadian Cancer Trials Group (CCTG)] helped change this.
View Article and Find Full Text PDFUltra-low dose rate brachytherapy (uLDR-BT) in treatment of patients with unfavorable intermediate-risk group prostate cancer - retrospective analysis.
Rep Pract Oncol Radiother
December 2024
Brachytherapy Department, Greater Poland Cancer Centre, Poznan, Poland.
Background: Treatment with sole ultra-low dose rate brachytherapy (uLDR-BT) for unfavorable intermediate risk factor (IUR) group prostate cancer patients is not recommended by guidelines due to the lack of strong evidence of its effectiveness. However, there were numerous patients treated with good results with this method in older trials. Purpose of this work was to retrospectively asses effectiveness of uLDR-BT in IUR group treated in our department.
View Article and Find Full Text PDFUnveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactions.
Front Immunol
December 2024
Department of Urology, The Second People's Hospital of Meishan City, Meishan, Sichuan, China.
Background: Prostate cancer (PCa) is a multifactorial and heterogeneous disease, ranking among the most prevalent malignancies in men. In 2020, there were 1,414,259 new cases of PCa worldwide, accounting for 7.3% of all malignant tumors.
View Article and Find Full Text PDFAn online national quality assessment survey of prostate MRI reading: interreader variability in prostate volume measurement and PI-RADS classification.
Eur J Radiol Open
June 2025
Institution of Molecular Medicine and Surgery (MMK), Karolinska Institutet, Stockholm, Sweden.
Background: High-quality assessment of prostate MRI is fundamental in both clinical practice and screening. There is a lack of national level data on variability in prostate volume measurement and PI-RADS assessment. Methods of quality assurance need to be developed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!